Oxydevit, 0.0009 % 5 ml

Calcium and phosphorus metabolism regulator, 1α-hydroxyvitamin D3. Causes increased absorption of calcium and phosphorus in the intestine, increases their reabsorption in the kidneys; regulates bone mineralization.

Pharmacokinetics

After oral administration alfacalcidol is rapidly absorbed from the gastrointestinal tract. Tmax of the active substance in plasma is from 8 to 18 hours.

Alfacalcidol is metabolized in the liver to form the main active metabolite calcitriol (1α,25-dihydroxyvitamin D3). A smaller portion of the active substance is metabolized in bone tissue.

Indications

Osteodystrophy (including chronic renal failure), hypoparathyreosis and pseudohypoparathyreosis, rickets and osteomalacia of different genesis, osteoporosis (including postmenopausal postmenopausal, senile, steroidal), renal acidosis, Fanconi syndrome (hereditary renal acidosis with nephrocalcinosis, tardive rickets and adiposogenital dystrophy).

Active ingredient

Composition

Active ingredient:

alphacalcidol 9 mcg.

How to take, the dosage

It is administered orally regardless of meals.

In children with rickets, 0.0005-0.003 mg/day depending on age and body weight for 2-3 months, sometimes up to 1 year. In rickets it is used 0.001 mg/day every day for 10 days. Three courses are carried out with a two-week break between them.

In chronic renal failure in children undergoing hemodialysis (a method of blood purification) to stop (relieve) osteodystrophy, 0.001 mg/day is given with simultaneous administration of vitamin D2 at 2,000 ME daily for an extended period.

Adults with chronic renal failure who are on hemodialysis are prescribed 0.001-0.002 mg/day daily or every other day with subsequent dose reduction to 0.0005 mg depending on normalization of blood calcium and alkaline phosphatase activity.

Courses of 2-3 months are recommended to be repeated 2-3 times a year.

In chronic renal insufficiency preliminary correction of hyperphosphatemia is required (normalization of increased content of phosphorus in blood).
Patients after renal transplantation for prophylactic purpose should take 0.00025-0.001 mg daily or every other day.

In case of bone pathology (osteoporosis, osteomalacia) of different origins the preparation is prescribed 0.0005-0.003 mg/day for a long period of time (from 2-3 months to 1 year and longer).
Oxidavit therapy is necessary under continuous monitoring of blood calcium and phosphorus content and alkaline phosphatase activity (weekly monitoring in chronic renal insufficiency).

Special Instructions

With caution use in patients with increased risk of hypercalcemia, especially in urolithiasis.

During treatment the plasma and urinary calcium levels should be monitored regularly, the development of therapeutic effect should be monitored and if necessary the dose of alfacalcidol should be adjusted to avoid the development of hypercalcemia and hypercalciuria.

Unlike natural vitamin D, alfacalcidol is not metabolized in the kidneys. There are reports on the effectiveness of alfacalcidol in secondary hyperparathyroidism due to renal insufficiency.

Contraindications

Hypercalcemia, hyperphosphatemia (except hyperphosphatemia in hyperparathyroidism), hypermagnesemia, vitamin D intoxication, lactation (breastfeeding), hypersensitivity to alfacalcidol.

Side effects

An allergic reaction is possible, and in case of overdose, hypercalcemia, which usually subsides 2-3 days after discontinuation of the drug. The drug is prescribed again in lower doses.

Pregnancy use

Oxydevit is contraindicated in pregnancy and lactation.

Similarities